Novavax (United States)

Recent papers from Novavax (United States)

1. Risk of Preterm Birth, Congenital Structural Anomalies and Severe Postpartum Hemorrhage After Receipt of NVX-CoV2373 Vaccine During PregnancyThe Pediatric Infectious Disease Journal · 2026
2. An Unconditional Exponential Upper Bound for the Windowed Weil Quadratic Form2026
3. Real-world evaluation of 2023–2024 XBB.1.5 mRNA and protein-based COVID-19 vaccine reactogenicity from the randomized BEEHIVE trialHuman Vaccines & Immunotherapeutics · 2026
4. Real-World Utilization of the Novavax Adjuvanted Recombinant Protein COVID-19 Vaccine in France During the 2022–2024 PeriodVaccines · 2026
5. Vaccine Ligand Binding Assay DevelopmentBioanalysis · 2026
6. Real-world effectiveness and safety of protein-based and mRNA COVID-19 vaccines (BEEHIVE trial)Vaccine · 2026
7. Intranasal and intramuscular H5-Matrix-M nanoparticle vaccines protects against highly pathogenic H5N1 influenza virus in micenpj Vaccines · 2026
8. Safety and immunogenicity of a COVID-19–Influenza Combination nanoparticle vaccine (CIC) containing SARS-CoV-2 recombinant spike and quadrivalent influenza hemagglutinin with Matrix-M® adjuvant: A phase 1/2 clinical trialHuman Vaccines & Immunotherapeutics · 2026
9. The Evolution, Capabilities, Limitations, and Future of Large Language Models (2026): A Comprehensive Review2026
10. Validation of a Mucosal IgA Assay for SARS-CoV-2Microorganisms · 2026
11. Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2 Omicron JN.1 and LP.8.1 Subvariant Lineage Strains with Homologous and Heterologous Matched Sera in Clinically Relevant SamplesMicroorganisms · 2026
12. Vaccine Ligand Binding Assay Life Cycle Management, Assay Maintenance, Monitoring and TransferBioanalysis · 2026
13. mRNA and Protein Subunit COVID-19 Vaccine Reactogenicity and Their Relationship to Productivity for Healthcare Workers and First RespondersOpen Forum Infectious Diseases · 2026
14. Safety of Matrix-M–adjuvanted COVID-19, seasonal influenza, combination influenza-COVID-19, and malaria vaccines: a review of the evidenceExpert Review of Vaccines · 2026
15. Real-World Effectiveness and Noninferiority Evaluation and Comparison of Messenger RNA–Based and Protein-Based COVID-19 Vaccines: Protocol for the BEEHIVE Randomized Study With a Hybrid Effectiveness DesignSHILAP Revista de lepidopterología · 2026
16. A Computational Community Blind Challenge on Pan-Coronavirus Drug Discovery DataJournal of Chemical Information and Modeling · 2026
17. Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trialsVaccine · 2026
18. Abstract C066: Matrix-M adjuvant – A promising adjuvant for preventative and therapeutic cancer vaccines developmentCancer Immunology Research · 2026
19. Immunogenicity and safety of a recombinant spike protein COVID vaccine in patients with inflammatory bowel disease and transplant recipientVaccine · 2026
20. P-1657. Difference in reactogenicity events between mRNA and Protein-subunit Vaccines: Results from the Booster Epidemiological Evaluation of Health, Illness, and Vaccine Efficacy (BEEHIVE) Study, a U.S. randomized trial of 2023-2024 COVID-19 vaccines (XBB.1.5)Open Forum Infectious Diseases · 2026